Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Viatris closes Pacira buy, taking its pain bet live as mid-cap deal flow builds

With the $36.50-a-share tender complete and $90-100 million of revenue guided by year-end, Viatris has a new non-opioid pain franchise, and a crowded week of deals puts it in context.

18 Nov 2026 · CompePharma editorial

What happened

Viatris has completed its cash acquisition of Pacira BioSciences at $36.50 a share, closing after a tender offer in which about 66.46% of Pacira's shares were tendered. Viatris describes Pacira as a non-opioid pain company and expects the acquisition to bring $90-100 million of revenue by year-end.

The material available to us does not give the headline transaction value, the product-level revenue split or any synergy targets, so we do not estimate them here. The revenue expectation is the one hard commercial marker. It is a near-term contribution figure, which suggests Viatris wants the market to see an immediate top-line effect rather than a long-dated promise.

The 66.46% tender figure is the other detail worth noting. It shows that most, but not all, holders tendered. The story does not spell out how the remaining shares will be handled, so readers should check the closing documents for the mechanics.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →